Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is a leading biopharmaceutical company headquartered in Bangalore, India. With a global presence, Biocon manufactures generic active pharmaceutical ingredients (APIs) distributed across 120 countries, including key markets like the United States and Europe. Known for its biosimilar insulins, antibodies, and novel biologics, Biocon serves diverse medical needs worldwide. In India, its product range spans metabolics, oncology, immunotherapy, and nephrology, featuring renowned brands like INSUGEN, BASALOG, and CANMAb. Additionally, Biocon’s subsidiary, Syngene International Limited, operates as a contract research and development organization, enhancing the company’s research capabilities.
History of Biocon
Established in 1978 by Kiran Mazumdar with just Rs. 10,000, Biocon swiftly emerged as a global leader in biopharmaceuticals. Notable milestones include pioneering enzyme exports to the US and Europe in 1979 and securing USFDA approval for lovastatin production in 2001. Over the years, strategic collaborations and expansions propelled Biocon’s growth, leading to breakthroughs like the development of human insulin on a Pichia expression system and the launch of BIOMAb EGFR for cancer treatment. Key partnerships with global players like Abbott and Amgen further solidified its position.
In 2021, Biocon Biologics partnered with the Serum Institute of India to commercialize vaccines and biological drugs, amplifying its impact on public health. The acquisition of Viatris’ biosimilar assets in 2022 bolstered its standing in the biosimilars market, underscoring its commitment to advancing healthcare globally. Throughout its journey, Biocon has remained dedicated to innovation, shaping the biopharmaceutical landscape and improving patient outcomes worldwide.
Biocon Reports 57% Decline in Q4 Net Profit, Achieves Billion-Dollar Milestone in Biologics Segment
- Biocon’s consolidated net profit for Q4 FY24 declined by 57% to Rs 136 crore due to higher expenses.
- Total revenue in the fourth quarter saw a marginal increase to Rs 3,966 crore compared to the same period last year.
- Total expenses for Q4 rose to Rs 3,635 crore, reflecting the challenging operational environment.
- However, for the fiscal year ending March 31, 2024, Biocon witnessed a significant rise in consolidated net profit to Rs 1,022 crore compared to the previous fiscal year.
- Total revenue for the fiscal year surged to Rs 15,621 crore, showcasing steady growth in performance.
- The strong performance of the Biologics segment was a notable highlight, achieving a billion-dollar annual revenue milestone.
- Increased market shares and significant volume growth in key markets like the US, Europe, and emerging markets contributed to the positive momentum in the biosimilars business.
- Biocon’s strategic initiatives, including debt reduction and long-term collaborations for product distribution in India, contributed to its transformational journey in FY24.
- The company’s board recommended a final dividend of 50 paise per share for the fiscal year, reflecting its commitment to shareholders amidst challenging market conditions.
You can buy Biocon shares in India by opening a trading account with a broker. You will need to provide your personal details, such as your PAN number, bank details, and other personal documents. Once the trading account is opened, you can buy Biocon shares using the broker’s online trading platform. You can also buy Biocon shares through a mutual fund or a portfolio management service. Some online platforms to buy shares are Zerodha, Sharekhan, and Upstox.
| When | Maximum Price | Minimum Price |
| July 2024 | 357.10 | 310.53 |
| August 2024 | 371.39 | 322.95 |
| September 2024 | 386.24 | 335.86 |
| October 2024 | 378.67 | 329.28 |
| November 2024 | 393.82 | 342.45 |
| December 2024 | 397.76 | 345.87 |
As we step into July 2024, the maximum price of Biocon shares is projected to be ₹357.10, while the minimum price is expected to be ₹310.53. Moving forward, by December 2024, it is anticipated that the maximum price of Biocon shares will reach ₹397.76, showcasing potential growth throughout the year. The minimum price by December 2024 is expected to be ₹345.87, indicating stability and sustained investor confidence in Biocon shares over the year.
| When | Maximum Price | Minimum Price |
| January 2025 | 401.73 | 309.03 |
| February 2025 | 405.79 | 312.15 |
| March 2025 | 414.31 | 318.70 |
| April 2025 | 410.21 | 315.55 |
| May 2025 | 398.26 | 306.36 |
| June 2025 | 416.18 | 320.14 |
| July 2025 | 408.02 | 313.86 |
| August 2025 | 420.64 | 323.57 |
| September 2025 | 425.69 | 327.45 |
| October 2025 | 436.76 | 335.97 |
| November 2025 | 447.68 | 344.37 |
| December 2025 | 467.82 | 359.86 |
As we step into January 2025, the maximum price of Biocon shares is projected to be ₹401.73, with a minimum price of ₹309.03. Progressing through the year, by December 2025, it is anticipated that the maximum price will rise to ₹467.82, indicating significant potential growth. The minimum price by December 2025 is expected to be ₹359.86.
| When | Maximum Price | Minimum Price |
| January 2026 | 481.86 | 370.66 |
| February 2026 | 469.81 | 361.39 |
| March 2026 | 479.21 | 368.62 |
| April 2026 | 488.99 | 376.14 |
| May 2026 | 484.15 | 372.42 |
| June 2026 | 496.25 | 381.73 |
| July 2026 | 486.52 | 374.25 |
| August 2026 | 501.57 | 385.82 |
| September 2026 | 511.60 | 393.54 |
| October 2026 | 524.90 | 403.77 |
| November 2026 | 538.02 | 413.86 |
| December 2026 | 551.47 | 424.21 |
| When | Maximum Price | Minimum Price |
| January 2027 | 509.68 | 392.06 |
| February 2027 | 522.75 | 402.11 |
| March 2027 | 543.13 | 417.80 |
| April 2027 | 532.48 | 409.60 |
| May 2027 | 516.98 | 397.67 |
| June 2027 | 540.24 | 415.57 |
| July 2027 | 529.65 | 407.42 |
| August 2027 | 546.03 | 420.02 |
| September 2027 | 565.14 | 434.72 |
| October 2027 | 579.83 | 446.02 |
| November 2027 | 594.33 | 457.17 |
| December 2027 | 609.19 | 468.60 |
| When | Maximum Price | Minimum Price |
| January 2028 | 621.37 | 477.98 |
| February 2028 | 637.30 | 490.23 |
| March 2028 | 662.16 | 509.35 |
| April 2028 | 649.17 | 499.36 |
| May 2028 | 630.27 | 484.82 |
| June 2028 | 658.63 | 506.64 |
| July 2028 | 645.71 | 496.70 |
| August 2028 | 665.68 | 512.06 |
| September 2028 | 688.98 | 529.99 |
| October 2028 | 706.90 | 543.77 |
| November 2028 | 724.57 | 557.36 |
| December 2028 | 742.68 | 571.29 |
| When | Maximum Price | Minimum Price |
| January 2029 | 757.54 | 582.72 |
| February 2029 | 776.96 | 597.66 |
| March 2029 | 807.26 | 620.97 |
| April 2029 | 791.43 | 608.79 |
| May 2029 | 768.38 | 591.06 |
| June 2029 | 802.96 | 617.66 |
| July 2029 | 787.21 | 605.55 |
| August 2029 | 811.56 | 624.28 |
| September 2029 | 839.97 | 646.13 |
| October 2029 | 861.80 | 662.93 |
| November 2029 | 883.35 | 679.50 |
| December 2029 | 905.43 | 696.49 |
| When | Maximum Price | Minimum Price |
| January 2030 | 923.54 | 710.42 |
| February 2030 | 947.22 | 728.63 |
| March 2030 | 984.16 | 757.05 |
| April 2030 | 964.87 | 742.21 |
| May 2030 | 936.76 | 720.59 |
| June 2030 | 978.92 | 753.01 |
| July 2030 | 959.72 | 738.25 |
| August 2030 | 989.41 | 761.08 |
| September 2030 | 1,024.04 | 787.72 |
| October 2030 | 1,050.66 | 808.20 |
| November 2030 | 1,076.93 | 828.41 |
| December 2030 | 1,103.85 | 849.12 |
As we move through 2030, Biocon’s share prices are projected to show monthly variations. In January 2030, Biocon’s maximum share price will be ₹923.54, while the minimum will be ₹710.42. By December 2030, the maximum share price is expected to reach ₹1,103.85, with the minimum at ₹849.12.
Biocon Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 |
| Expenses + | 4,725 | 5,562 | 6,391 | 8,762 | 11,541 |
| Operating Profit | 1,575 | 1,581 | 1,793 | 2,412 | 3,214 |
| OPM % | 25% | 22% | 22% | 22% | 22% |
| Other Income + | 228 | 260 | 72 | 18 | 854 |
| Interest | 65 | 58 | 68 | 419 | 974 |
| Depreciation | 552 | 715 | 814 | 1,113 | 1,569 |
| Profit before tax | 1,186 | 1,068 | 983 | 897 | 1,525 |
| Tax % | 27% | 21% | 22% | 28% | 15% |
| Net Profit + | 871 | 846 | 772 | 643 | 1,298 |
| EPS in Rs | 6.24 | 6.17 | 5.4 | 3.85 | 8.52 |
| Dividend Payout % | 0% | 0% | 9% | 39% | 6% |
Biocon’s financial performance over the years from March 2020 to March 2024 shows a steady increase in sales and operating profit. Sales grew from ₹6,300 crore in March 2020 to ₹14,756 crore in March 2024. Expenses also increased, reaching ₹11,541 crore in March 2024, leading to an operating profit of ₹3,214 crore with a consistent OPM of 22%.
Despite fluctuations in other income and rising interest and depreciation costs, Biocon’s profit before tax rose to ₹1,525 crore in March 2024. The company’s net profit improved significantly to ₹1,298 crore, and the EPS increased from ₹6.24 in March 2020 to ₹8.52 in March 2024.
Additionally, the tax rate decreased to 15% in March 2024, contributing to the higher net profit. However, the dividend payout varied, peaking at 39% in March 2023 before dropping to 6% in March 2024.
Also Read
- BOSCH SHARE PRICE TARGET 2023, 2024, 2025, 2026 TO 2030
- Paytm (One97) Share Price Target 2024, 2025, 2026 to 2030: Should you buy PAYTM?
- Berger Paints India Stock Price Target: 2024, 2025, 2026 to 2030
FAQs
Will Biocon stock price grow in 2024?
Yes, Biocon stock price is expected to grow in 2024. The company’s current share price is around Rs 345, and analysts have estimated that Biocon price will reach ₹397.76 by the end of 2024.
What future is anticipated for Biocon in 2025?
Analysts expect Biocon’s stock price to reach Rs 467.82 by the end of 2025. Biocon focus on innovation and quality is expected to help it maintain its growth in the coming years.
In 2030, Biocon is expected to trade in between ₹710.42 and ₹1,103.85.
Conclusion:
In conclusion, Biocon’s Q4 results, and financial performance underscore the company’s strength and potential for future growth. Despite a temporary decline in net profit due to increased expenses, Biocon achieved significant annual revenue growth, reaching ₹15,621 crore for FY24. The Biologics segment’s billion-dollar milestone and strong market performance in key regions highlight the company’s strategic success.
Over the past five years, Biocon has consistently expanded its sales and operating profit, demonstrating robust financial health and operational efficiency. Strategic initiatives, including debt reduction and long-term collaborations, have further enhanced its market position.
Biocon’s unwavering commitment to innovation and global expansion positions it well for sustained growth. The company’s ability to adapt and thrive amidst challenges reinforces its potential to continue delivering value to stakeholders and making a significant impact on global healthcare.
What did we learn?
